Abstract
Platonin, a photosensitizing dye, is known to possess antioxidant and anti-inflammatory activity. Platonin has been used to treat trauma, ulcers and some acute inflammations and it also reported to improve blood circulation and reduce mortality in endotoxin-induced rat models. Our previous studies established that platonin suppresses the lipopolysaccharides (LPS)-induced inflammatory cytokines, including interleukin-1β (IL-1β-+), IL-6, tumor necrosis factor-α (TNF-α), and inducible nitric oxide synthase (iNOS). Nuclear factor-kB (NF-kB) and activator protein-1 (AP-1) transcription factors are reported to be essential in mediating the endotoxin-induced production of inflammatory molecules. In vivo studies from our groups revealed that platonin has potential effects on inhibiting pyrogen release, tissue damage and ischemia during heatstroke, ischemia reperfusion injury in lungs and also improve the survival of skin allografts in rats. Clinically, this compound has been proven to cure juvenile rheumatoid arthritis (JRA) and polyarteritis nodosa (PN). In this review, we summarize the pharmacological and clinical effects of platonin via describing the potential molecular mechanism of regulation of inflammatory molecules of mitogen-activated protein kinases (MAPKs), including extracellular regulated kinase (ERK), c-jun N-terminal kinase (JNK), and p38 MAPK and also NF-kB activation. Moreover, this paper discusses the signaling pathways expedited by NF-kB, AP-1, MAPKs and NO/NOS, these all have been reflected in inflammatory processes, and could be the encouraging molecular targets for the design of pharmaceutical drugs targeting antiinflammatory therapy.
Keywords: Clinical application, inflammatory event, pharmacological property, platonin, molecular target.
Related Journals
Related eBooks
Related Articles
-
Sexual Dysfunction among Women with Connective Tissue Disease
Current Rheumatology Reviews MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Current Drug Safety Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008
Current Topics in Medicinal Chemistry Mechanisms Leading to Autoantibody Production: Link Between Inflammation and Autoimmunity
Current Drug Targets - Inflammation & Allergy Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Interleukin-10 and Articular Cartilage: Experimental Therapeutical Approaches in Cartilage Disorders
Current Gene Therapy Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg
Current Rheumatology Reviews Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry Apoptotic Regulators and RA
Current Rheumatology Reviews Activation of Central Pain Pathways in Rheumatic Diseases: What We have Learned from Functional Neuroimaging Studies
Current Rheumatology Reviews Update on Therapeutic Approaches for Rheumatoid Arthritis
Current Medicinal Chemistry Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Suppression of Erosive Arthritis by NF-κB Inhibitors
Current Rheumatology Reviews Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Current Drug Safety TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine Etiological and Biological Aspects of Cigarette Smoking in Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design TNF-Alpha as a Therapeutic Target in Inflammatory Diseases, Ischemia- Reperfusion Injury and Trauma
Current Medicinal Chemistry